Neuroblastoma (NB), which arises from nerve tissue outside the brain, is the third most common tumor occurring during early childhood. High risk NBs with poor prognosis show very few mutations but a typical recurrent pattern of gains or losses of chromosomal segments. The latter are assumed to result in dosage effects for proteins contributing to tumor formation and/or progression.
My research focusses on transcription factors (TFs) and epigenetic rewiring driving transcriptional addiction in neuroblastoma. In my project, I propose to investigate in further detail an exciting novel finding made by dr. Bieke Decaesteker (PhD) who has shown tumor dependency for the highly expressed SOX11 protein. Further work includes the study of target genes and the underlying molecular pathways regulated by this TF. This will ultimately lead to the understanding of the fundamental underlying mechanisms of NB which may contribute to novel targeted therapies.
I obtained a Bachelor’s Degree in Biochemistry and Biotechnology (KU Leuven, 2016), after which I obtained a Master Degree in Biochemistry with a major in Molecular and Cellular Genetics (LMU München, 2018).
For my master thesis, I went to the lab of Prof. Jürg Schwaller (UKBB Basel), where I focused on the molecular mechanism driving acute erythroid leukemia.
After my master thesis, I started a PhD (October 2018, Kom op tegen Kanker Fellowship) at the lab of Prof. Speleman, where I investigate the transcription factors (TFs) and epigenetic rewiring driving transcriptional addiction in neuroblastoma.
Contact & links
- Lab address: Center for Medical Genetics Ghent (CMGG), Medical Research Building 1 (MRB1), campus UZ Gent, (entrance 34 ), Corneel Heymanslaan 10, 9000 Ghent, Belgium
- Speleman Lab
- Center for Medical Genetics Ghent
- Kom op tegen Kanker
- Amber Louwagie is interested to receive invitations for presentations or talks